ଆଲୋଗ୍ଲିପଟିନ

ଆଲୋଗ୍ଲିପଟିନ
Clinical data
Trade names	Nesina, Vipidia; Kazano, Vipidomet (with metformin); Oseni, Incresync (with pioglitazone)
Synonyms	Alogliptin benzoate, SYR-322
AHFS/Drugs.com	monograph
MedlinePlus	a613026
data	EU EMA: yes; US DailyMed: Alogliptin;
Pregnancy; category	AU: B3 ; US: B (No risk in non-human studies) ; ;
Routes of; administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	100%
Protein binding	20%
Metabolism	Limited, liver (CYP2D6- and 3A4-mediated)
Elimination half-life	12–21 hours
Excretion	Kidney (major) and fecal (minor)
Identifiers
	IUPAC name 2-({6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile;
ECHA InfoCard	100.256.501
Chemical and physical data
Formula	C18H21N5O2
Molar mass	୩୩୯.୪0 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC[C@@H](N)C2;
	InChI InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1 ; Key:ZSBOMTDTBDDKMP-OAHLLOKOSA-N ;
(verify)

ଆଲୋଗ୍ଲିପଟିନ, ବେପାର ନାମ ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ନେସିନା ଏବଂ ଭିପିଡିଆ, ଏକ ଔଷଧ ଯାହା ଟାଇପ୍-୨ ମଧୁମେହର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ ।^[୧] ଏହା ହେଉଛି ଦ୍ୱିତୀୟ ଧାଡ଼ିର ଚିକିତ୍ସା ଯାହା ଖାଦ୍ୟ ଏବଂ ବ୍ୟାୟାମ ସହିତ ମିଳିତ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ । ^[୨] ହୃଦ୍‌ରୋଗର ଆଶଙ୍କା ଉପରେ ପ୍ରଭାବ ଅସ୍ପଷ୍ଟ। ^[୧] ଏହା ପାଟିରେ ଦିଆଯାଏ । ^[୩]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ନାକରୁ ପାଣି ବୋହିବା, ମୁଣ୍ଡବିନ୍ଧା ଏବଂ ଉପର ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ ହୋଇପାରେ । ^[୧] ଅନ୍ୟାନ୍ୟପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଅଗ୍ନାଶୟ ପ୍ରଦାହ, ହୃଦ୍‌ପାତ, ଆନାଫାଇଲାକ୍‌ସିସ୍, ଯକୃତ ସମସ୍ୟା ଏବଂ କମ୍ ରକ୍ତ ଶର୍କରା ହୋଇପାରେ। ^[୧] ଗର୍ଭାବସ୍ଥାରେ ସୁରକ୍ଷା ଅସ୍ପଷ୍ଟ ଅଟେ। ^[୧] ଏହା ଏକ ଡିପିପି-୪ (DPP-4) ଇନହିବିଟର (ଗ୍ଲିପଟିନ୍), ଯାହା ଅଗ୍ନାଶୟରୁ ଇନସୁଲିନ୍ କ୍ଷରଣ ବୃଦ୍ଧି କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ । ^[୧] ^[୩]

୨୦୧୩ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ର ଏବଂ ୟୁରୋପରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଆଲୋଗ୍ଲିପଟିନ ଅନୁମୋଦିତ ହୋଇଥିଲା। ^[୧]^[୪] ଯୁକ୍ତରାଜ୍ୟରେ ୨୦୨୧ ସୁଦ୍ଧା ଏହାର ମୂଲ୍ୟ ପ୍ରାୟ ୨୭ ପାଉଣ୍ଡ ଅଟେ। ।^[୩] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ପରିମାଣର ମୂଲ୍ୟ ୯୦ ଡଲାର ।^[୫] ଏହା ମେଟଫର୍ମିନ୍ କିମ୍ବା ପିଓଗ୍ଲିଟାଜୋନ୍ ସହିତ ଏକ ମିଶ୍ରିତ ଔଷଧ ଭାବରେ ମଧ୍ୟ ଉପଲବ୍ଧ । ^[୨]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "DailyMed - ALOGLIPTIN tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 10 November 2021. Retrieved 14 January 2022.
↑ ^୨.୦ ^୨.୧ "Alogliptin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 January 2021. Retrieved 14 January 2022.
↑ ^୩.୦ ^୩.୧ ^୩.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 734. ISBN 978-0857114105.
↑ "Vipidia". Archived from the original on 16 November 2021. Retrieved 14 January 2022.
↑ "Alogliptin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 January 2022.

[PI2022-1] ୧.୦ ^୧.୧ ^୧.୨ ^୧.୩ ^୧.୪ ^୧.୫ ^୧.୬ "DailyMed - ALOGLIPTIN tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 10 November 2021. Retrieved 14 January 2022.

[AHFS2022-2] ୨.୦ ^୨.୧ "Alogliptin Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 28 January 2021. Retrieved 14 January 2022.

[BNF81-3] ୩.୦ ^୩.୧ ^୩.୨ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 734. ISBN 978-0857114105.

[EPAR2022-4] "Vipidia". Archived from the original on 16 November 2021. Retrieved 14 January 2022.

[5] "Alogliptin Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 14 January 2022.

[୧]

[୨]

[୩]

[୪]

[୫]

Clinical data

Trade names	Nesina, Vipidia Kazano, Vipidomet (with metformin) Oseni, Incresync (with pioglitazone)
Synonyms	Alogliptin benzoate, SYR-322
AHFS/Drugs.com	monograph
MedlinePlus	a613026
data	EU EMA: yes US DailyMed: Alogliptin
Pregnancy category	AU: B3 US: B (No risk in non-human studies)
Routes of administration	By mouth
Legal status
Legal status	AU: S4 (Prescription only) US: ℞-only EU: Rx-only ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	100%
Protein binding	20%
Metabolism	Limited, liver (CYP2D6- and 3A4-mediated)
Elimination half-life	12–21 hours
Excretion	Kidney (major) and fecal (minor)
Identifiers
IUPAC name 2-({6-[(3R)-3-Aminopiperidin-1-yl]-3-methyl-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl}methyl)benzonitrile
ECHA InfoCard	100.256.501
Chemical and physical data
Formula	C₁₈H₂₁N₅O₂
Molar mass	୩୩୯.୪0 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES N#Cc3ccccc3CN\1C(=O)N(C)C(=O)/C=C/1N2CCC[C@@H](N)C2
InChI InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1^Y Key:ZSBOMTDTBDDKMP-OAHLLOKOSA-N^Y
(verify)